| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| HLA-A*0201 & B2M & Survivin (TLPPAWQPFL) | Biotinylated Human HLA-A*02:01&B2M&Survivin (TLPPAWQPFL) Complex Protein (Monomer, MALS verified) |  Human | HEK293 | MALSSDS-PAGE | $125.00 25ug | |||
| HLA-A*0201 & B2M & Survivin (TLPPAWQPFL) | PE-Labeled Human HLA-A*02:01&B2M&Survivin (TLPPAWQPFL) Tetramer Protein | Human | HEK293 | $410.00 25ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| AFX-5931 | AFX-5931 | Phase 2 Clinical | Eczema | Details | |
| MW-151 | MW01-9-034WH; MW-151; MW01-2-151SRM | Phase 1 Clinical | University Of Kentucky | Drug-Related Side Effects and Adverse Reactions; Poisoning; Cognition Disorders | Details |
| 64CU-DOTA-ECL1i | Phase 1 Clinical | Washington University School Of Medicine | Carotid Artery Diseases; Heart Diseases; Arteriosclerosis | Details |
